The oncology field continues to evolve rapidly in areas of cancer biology and in harnessing immune biology for next generation therapies. We are prioritizing our emerging pipeline efforts in the pursuit of curative therapies, with a focus on novel mechanisms in the cancer-immunity cycle.

**MARKETED AND LATE STAGE**

<table>
<thead>
<tr>
<th><strong>HEMATOLOGIC MALIGNANCIES</strong></th>
<th><strong>SOLID TUMORS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BRENTUXIMAB VEDOTIN*</td>
<td>CDB-Targeted Antibody Drug Conjugate</td>
</tr>
<tr>
<td>IXAZOMIB</td>
<td>Proteasome Inhibitor Multiple Myeloma</td>
</tr>
<tr>
<td>PONATINIB*</td>
<td>FLT-3 Inhibitor</td>
</tr>
<tr>
<td>PEVONEDISTAT</td>
<td>Higher-Risk Myelodysplastic Syndromes</td>
</tr>
<tr>
<td></td>
<td>Low-Blast Acute Myelogenous Leukemia</td>
</tr>
</tbody>
</table>

**HEMATOLOGIC MALIGNANCIES**

- **BRENTUXIMAB VEDOTIN**: CD30-Targeted Antibody Drug Conjugate
- **IXAZOMIB**: Proteasome Inhibitor Multiple Myeloma
- **PONATINIB**: FLT-3 Inhibitor
- **PEVONEDISTAT**: Higher-Risk Myelodysplastic Syndromes

**SOLID TUMORS**

- **BRIGATINIB**: Anaplastic Lymphoma Kinase Inhibitor ALK+ Non-Small Cell Lung Cancer
- **MOBOCERTINIB**: EGFR/HER2 Inhibitor Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

**PIPELINE**

**NEXT-GEN INNATE AND CHECKPOINT MODULATORS**

- **TAK-981**: SUPP-Activating Epinephrine Vascular Tumor Necrosis Factor Inhibitor
- **TAK-676**: STRL5-Antagonist Solid Tumors
- **TAK-605**: CAR-T Neomycin Solid Tumors
- **TAK-169**: CD3-Targeted Neomycin T-cell Engager Solid Tumors
- **TAK-186**: Conditional Checkpoint Antibody Tumor Necrosis Solid Tumors
- **TAK-573**: CD38 Attenukine Solid Tumors Multiple Myeloma

**CELL THERAPY**

- **TAK-940**: CD19 CAR-NK Relapsed/Refractory B-Cell Malignancies
- **TAK-102**: UC-SC-102 Solid Tumors

**MARKETED AND LATE STAGE**

**HEMATOLOGIC MALIGNANCIES**

- **BRENTUXIMAB VEDOTIN**: CD30-Targeted Antibody Drug Conjugate
- **IXAZOMIB**: Proteasome Inhibitor Multiple Myeloma
- **PONATINIB**: FLT-3 and ABL Inhibitor

**SOLID TUMORS**

- **BRIGATINIB**: Anaplastic Lymphoma Kinase Inhibitor ALK+ Non-Small Cell Lung Cancer
- **MOBOCERTINIB**: EGFR/HER2 Inhibitor Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

**ALL PRODUCTS LISTED ARE INVESTIGATIONAL IN THE SETTING IN WHICH THEY ARE CURRENTLY BEING STUDIED AND NOT APPROVED FOR THESE INDICATIONS. SAFETY AND EFFICACY NOT YET ESTABLISHED (SEE CLINICALTRIALS.GOV).**

*References and Notes:
- Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. Takeda shares development rights with Seattle Genetics.
- Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories).
- Japan Only. In partnership with Exelixis, Inc.
- Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia.
- Japan and Asian countries. In partnership with Myovant Sciences, Inc.
- Under licensing agreement and in collaboration with MD Anderson Cancer Center.
- Collaboration with Noile-Immune Biotech.
- Takeda retains an option to develop TAK-252 / SL-279252 with Shattuck Labs.
- In Collaboration with Turnstone Biologics.
- Takeda shares development rights for TAK-186 with Maverick Pharma Pvt. Ltd.
- In Collaboration with Memorial Sloan Kettering Cancer Center.

**TAKEDA**

Reference: https://www.takeda.com (last accessed: November, 2020)